From pitching at Microsoft’s Singapore office to conversations with APAC health systems — our week at the Singapore Week of Innovation and Technology (SWITCH) confirmed what clinical partners worldwide are looking for from AI in healthcare.
We’re back from Singapore — energised, grateful, and with a clearer picture than ever of where clinical AI needs to go next.
As part of the Eureka Network delegation, Aisthesis Medical attended the Singapore Week of Innovation and Technology (SWITCH) — one of Asia’s premier platforms for connecting global innovators, investors, and enterprise partners across the technology spectrum. For a company building clinical AI for global hospital markets, it was exactly the right room to be in
What SWITCH Is — and Why It Mattered for Us
SWITCH is organised by Enterprise Singapore and brings together thousands of startups, corporates, investors, and government bodies across industries — with a particular emphasis on deep tech, healthtech, and AI. It’s one of the few global innovation events with a genuine APAC-first perspective, attracting participants from across Southeast Asia, East Asia, Australia, and beyond.
For Aisthesis Medical, attending as part of the Eureka Network — the world’s largest public research and innovation network — opened doors to conversations with health systems, technology partners, and ecosystem builders that simply aren’t accessible through European-only channels. Expanding VIOSync’s reach into APAC healthcare markets is a strategic priority, and SWITCH was a pivotal step in that direction.
Pitching at Microsoft Singapore: What We Heard
A standout moment of the week was the opportunity to pitch VIOSync at Microsoft’s Singapore office, alongside a cohort of high-calibre global startups. Presenting to Microsoft leadership — with their deep expertise in enterprise AI, cloud infrastructure, and healthcare technology at scale — was both a challenge and an opportunity.
The feedback was clear and directly aligned with our product direction. Three themes dominated:
- Explainability is non-negotiable: Enterprise health systems — whether NHS trusts or APAC hospital networks — will not deploy AI they can’t explain to clinicians, regulators, and patients. VIOSync’s Explainable AI (XAI) approach was seen as a genuine differentiator.
- Security at the infrastructure level: As health systems move toward cloud-connected AI, security posture becomes a procurement prerequisite — not a nice-to-have.
- Enterprise deployment readiness: The ability to integrate cleanly with existing hospital IT infrastructure — without creating new workflow burdens — is what separates clinical AI that scales from clinical AI that pilots forever.
Every one of those themes is central to how VIOSync is built. The session confirmed that our product priorities are well-calibrated for the enterprise healthcare market — not just in Europe, but globally.
The Signal from APAC Healthcare Partners
Beyond the Microsoft pitch, the week was packed with conversations across cloud infrastructure, data interoperability, and responsible AI deployment — with healthcare partners spanning Singapore, Southeast Asia, and further afield.
The takeaway was consistent and striking: healthcare systems in the APAC region are not looking for more dashboards. They’re not looking for another standalone monitoring tool that adds to clinical noise. They want explainable intelligence that plugs in cleanly and delivers measurable impact.
That’s precisely what VIOSync is designed to be. The alignment between what APAC health systems are demanding and what we’re building — predictive, explainable, workflow-integrated, evidence-ready — gives us strong confidence in the international market opportunity ahead.
What Comes Next: APAC Evaluations and Pilots
SWITCH wasn’t a conversation endpoint — it was the beginning of several. We’re now actively scheduling follow-up discussions with health systems across the APAC region to scope formal evaluations and pilot programmes for VIOSync.
The message from Singapore: the time for predictive, explainable, enterprise-ready clinical AI is now. We’re building exactly that — and the global healthcare ecosystem is paying attention.
About Aisthesis Medical
Aisthesis Medical is a deep-tech medtech startup developing cutting-edge AI-driven solutions to revolutionize acute care. Founded in 2022, our mission is to save lives by predicting and preventing sepsis before it becomes fatal. Aisthesis Medical is revolutionizing acute care with VIOSync, the first holistic AI-driven sepsis care platform that goes beyond early prediction to guide clinical intervention and optimize patient outcomes. VIOSync, predicts sepsis up to 48 hours earlier, integrates directly into hospital workflows, and optimizes treatment pathways to reduce unnecessary antibiotic use.
Ready to Learn More?
If you’re a hospital, NHS trust, or healthcare investor interested in learning more about VIOSync or our security and compliance posture, we’d love to connect.
📩 Get in touch: https://aisthesismed.com/contact/
🌐 Learn more about VIOSync: https://aisthesismed.com/product/